Compare AFCG & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFCG | LONA |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.4M | 71.2M |
| IPO Year | 2020 | 2020 |
| Metric | AFCG | LONA |
|---|---|---|
| Price | $3.53 | $4.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.33 |
| AVG Volume (30 Days) | 66.9K | ★ 125.6K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $24,563,601.00 | N/A |
| Revenue This Year | $1,384.82 | N/A |
| Revenue Next Year | $1.29 | N/A |
| P/E Ratio | $5.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.06 | $2.21 |
| 52 Week High | $4.01 | $14.21 |
| Indicator | AFCG | LONA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 24.85 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $8.77 |
| Average True Range (ATR) | 0.00 | 0.84 |
| MACD | 0.00 | -0.33 |
| Stochastic Oscillator | 0.00 | 21.11 |
Advanced Flower Capital Inc is an externally managed Maryland corporation that operates as a Business Development Company (BDC). The firm's primary operations involve originating, structuring, underwriting, and managing senior secured loans and other debt securities. Its investment portfolio includes loans to state law-compliant cannabis operators, ancillary cannabis businesses, and middle-market companies in other industries. These loans are typically secured by collateral such as real estate, equipment, cash flows, and license values.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.